Research programme: protectans - Statera BioPharma
Alternative Names: CBLB 613; Pifithrin-muLatest Information Update: 02 Sep 2021
At a glance
- Originator Cleveland BioLabs
- Developer Statera BioPharma
- Class Proteins; Small molecules
- Mechanism of Action Stem cell stimulants; Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemotherapy-induced damage; Radiation injuries
Most Recent Events
- 01 Sep 2021 Cytocom is now called Statera BioPharma
- 28 Jul 2021 Cytocom has been merged with Cleveland BioLabs to form Cytocom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chemotherapy-induced-damage(Prevention) in USA (Parenteral, Injection)